Executives at Deutsche Bank AG are contemplating dramatic options for the German lender, including selling all or part of a key business, a sign of growing pressure to speed up a flagging overhaul.
This weekend, senior executives are meeting to debate some of these options, according to people familiar with the plans. One has already been floated: a merger with Germany’s second-largest bank by market value, Commerzbank AG, the people said. Deutsche Bank and Commerzbank held preliminary discussions about a tie-up in August, before concluding last week it wasn’t viable.
Chief Executive John Cryan, who was named co-CEO in July 2015, has set out a long-term plan of shrinking Deutsche Bank and cutting costs. But the merger discussions and the weekend summit signify that the bank may not have the luxury of a drawn-out revamp. On Wednesday, Mr. Cryan found himself on stage at a financial conference in Frankfurt batting back speculation about a merger.
Top 5 Value Stocks To Own For 2018: Orexigen Therapeutics, Inc.(OREX)
Advisors’ Opinion:
- [By Peter Graham]
A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:
- [By Cameron Saucier]
Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).
- [By Keith Speights]
Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.
Top 5 Value Stocks To Own For 2018: Navigant Consulting, Inc.(NCI)
Advisors’ Opinion:
- [By Lisa Levin]
Shares of Navigant Consulting, Inc. (NYSE: NCI) were down 14 percent to $17.02 after the company posted downbeat quarterly results.
Hertz Global Holdings, Inc (NYSE: HTZ) was down, falling around 18 percent to $14.24. Barclays downgraded Hertz from Equal-Weight to Underweight.
Top 5 Value Stocks To Own For 2018: Cal-Maine Foods, Inc.(CALM)
Advisors’ Opinion:
- [By Lisa Levin]
Some of the stocks that may grab investor focus today are:
Wall Street expects Rite Aid Corporation (NYSE: RAD) to report quarterly earnings at $0.04 per share on revenue of $8.23 billion before the opening bell. Rite Aid shares gained 0.83 percent to $8.54 in after-hours trading.
Micron Technology, Inc. (NASDAQ: MU) reported better-than-expected profit for its first quarter and issued a strong forecast for the current quarter. Micron shares climbed 9.91 percent to $22.62 in the after-hours trading session.
Analysts expect Cal-Maine Foods Inc (NASDAQ: CALM) to post quarterly earnings at $0.48 per share on revenue of $262.83 million after the closing bell. Cal-Maine shares rose 0.12 percent to $42.75 in after-hours trading.
Red Hat Inc (NYSE: RHT) reported upbeat earnings for its third quarter, but sales missed expectations. The company also announced that its CFO Frank Calderoni is stepping down. Red Hat shares tumbled 10.15 percent to $71.69 in the after-hours trading session.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Tyler Crowe, Jordan Wathen, and Beth McKenna]
So we asked three of our contributors to highlight a stock they see as a real underdog in the market today and why investors should be watching this stock. Here’s a quick look into why they picked banker Wells Fargo (NYSE:WFC), railcar manufacturer Greenbrier Companies (NYSE:GBX) , and egg wholesaler Cal-Maine Foods (NASDAQ:CALM)
- [By Craig Jones]
On CNBC's Fast Money Halftime Report, Jon Najarian said that Cal-Maine Foods Inc (NASDAQ: CALM) had unusually high options volume on Friday. Traders were buying the May 45 calls and Jon Najarian decided to follow the trade. He is planning to hold the position for 1 to 2 months.
Top 5 Value Stocks To Own For 2018: Marvell Technology Group Ltd.(MRVL)
Advisors’ Opinion:
- [By Lisa Levin]
Marvell Technology Group Ltd. (NASDAQ: MRVL) shares shot up 10 percent to $14.70 after the company reported upbeat Q3 results and announced a $1 billion share buyback.
- [By Chris Lange]
When Marvell Technology Group Ltd. (NASDAQ: MRVL) released its fiscal third-quarter results after the markets closed on Tuesday, it posted $0.34 in earnings per share (EPS) and $616.3 million in revenue. Consensus estimates had called for $0.33 in EPS on revenue of $613.1 million. The same period of last year reportedly had EPS of $0.21 and $604.75 million in revenue.
- [By Lisa Levin]
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday’s regular session.
- [By Peter Graham]
Mid cap fabless semiconductor stock Marvell Technology Group Ltd (NASDAQ: MRVL) reported fiscal Q1 2018 earnings after the Thursday market close that beat expectations. Net revenue was $579.180 million versus $519.383 million andnet income was $96.970 million versus a net loss of $13.271 million. The CEO commented:
Top 5 Value Stocks To Own For 2018: Xerium Technologies Inc.(XRM)
Advisors’ Opinion:
- [By kiplinger]
52-week high: $18.93
52-week low: $11.01Annual revenues: $492.9 million
Xerium Technologies (XRM), a manufacturer of products used in papermaking, is a favorite of micro-cap expert Dan Abramowitz, who heads Hillson Financial Management, in Rockville, Md. Abramowitz calls the company “a turnaround story that is now at an inflection point.” Changes that a new management team put into effect in 2012 should start bearing fruit. The stock’s price-earnings ratio is a mere 7, based on the average of analysts’ earnings estimates for 2016.
